Annual Cash & Cash Equivalents
$22.46 M
-$23.88 M-51.53%
31 December 2023
Summary:
Lexicon Pharmaceuticals annual cash & cash equivalents is currently $22.46 million, with the most recent change of -$23.88 million (-51.53%) on 31 December 2023. During the last 3 years, it has fallen by -$103.80 million (-82.21%). LXRX annual cash & cash equivalents is now -88.93% below its all-time high of $202.99 million, reached on 31 December 2015.LXRX Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly Cash And Cash Equivalents
$34.55 M
-$1.07 M-2.99%
30 September 2024
Summary:
Lexicon Pharmaceuticals quarterly cash and cash equivalents is currently $34.55 million, with the most recent change of -$1.07 million (-2.99%) on 30 September 2024. Over the past year, it has increased by +$13.44 million (+63.62%). LXRX quarterly cash and cash equivalents is now -86.72% below its all-time high of $260.13 million, reached on 31 March 2010.LXRX Quarterly Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
LXRX Cash And Cash Equivalents Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -51.5% | +63.6% |
| 3 y3 years | -82.2% | -62.5% |
| 5 y5 years | -72.0% | -79.7% |
LXRX Cash And Cash Equivalents High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3 years | -82.2% | at low | -66.2% | +83.5% |
| 5 y | 5 years | -82.2% | at low | -79.7% | +83.5% |
| alltime | all time | -88.9% | +1008.8% | -86.7% | +1928.6% |
Lexicon Pharmaceuticals Cash And Cash Equivalents History
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2024 | - | $34.55 M(-3.0%) |
| June 2024 | - | $35.62 M(-63.1%) |
| Mar 2024 | - | $96.49 M(+329.5%) |
| Dec 2023 | $22.46 M(-51.5%) | $22.46 M(+6.4%) |
| Sept 2023 | - | $21.12 M(-79.4%) |
| June 2023 | - | $102.27 M(+293.3%) |
| Mar 2023 | - | $26.00 M(-43.9%) |
| Dec 2022 | $46.34 M(-27.7%) | $46.34 M(+146.1%) |
| Sept 2022 | - | $18.83 M(-12.2%) |
| June 2022 | - | $21.45 M(-64.0%) |
| Mar 2022 | - | $59.52 M(-7.1%) |
| Dec 2021 | $64.06 M(-49.3%) | $64.06 M(-30.5%) |
| Sept 2021 | - | $92.12 M(+2.5%) |
| June 2021 | - | $89.89 M(-8.0%) |
| Mar 2021 | - | $97.65 M(-22.7%) |
| Dec 2020 | $126.26 M(+249.6%) | $126.26 M(+141.6%) |
| Sept 2020 | - | $52.25 M(-39.9%) |
| June 2020 | - | $86.94 M(+56.4%) |
| Mar 2020 | - | $55.59 M(+53.9%) |
| Dec 2019 | $36.11 M(-55.1%) | $36.11 M(-78.8%) |
| Sept 2019 | - | $170.20 M(+1432.5%) |
| June 2019 | - | $11.11 M(-75.7%) |
| Mar 2019 | - | $45.78 M(-43.1%) |
| Dec 2018 | $80.39 M(+30.4%) | $80.39 M(+64.4%) |
| Sept 2018 | - | $48.90 M(+225.1%) |
| June 2018 | - | $15.04 M(-26.3%) |
| Mar 2018 | - | $20.42 M(-66.9%) |
| Dec 2017 | $61.66 M(+32.3%) | $61.66 M(-26.0%) |
| Sept 2017 | - | $83.29 M(+171.3%) |
| June 2017 | - | $30.71 M(+1150.8%) |
| Mar 2017 | - | $2.46 M(-94.7%) |
| Dec 2016 | $46.60 M(-77.0%) | $46.60 M(+20.2%) |
| Sept 2016 | - | $38.77 M(+0.9%) |
| June 2016 | - | $38.41 M(+55.6%) |
| Mar 2016 | - | $24.68 M(-87.8%) |
| Dec 2015 | $202.99 M(+47.9%) | $202.99 M(+229.1%) |
| Sept 2015 | - | $61.67 M(+532.9%) |
| June 2015 | - | $9.74 M(-76.8%) |
| Mar 2015 | - | $41.96 M(-69.4%) |
| Dec 2014 | $137.27 M(+266.1%) | $137.27 M(+412.7%) |
| Sept 2014 | - | $26.77 M(-3.4%) |
| June 2014 | - | $27.73 M(-40.4%) |
| Mar 2014 | - | $46.52 M(+24.0%) |
| Dec 2013 | $37.50 M(+23.3%) | $37.50 M(+91.5%) |
| Sept 2013 | - | $19.58 M(-15.8%) |
| June 2013 | - | $23.25 M(-32.1%) |
| Mar 2013 | - | $34.25 M(+12.6%) |
| Dec 2012 | $30.42 M | $30.42 M(+46.6%) |
| Sept 2012 | - | $20.76 M(-38.5%) |
| June 2012 | - | $33.78 M(+16.4%) |
| Date | Annual | Quarterly |
|---|---|---|
| Mar 2012 | - | $29.01 M(-84.4%) |
| Dec 2011 | $186.31 M(+294.7%) | $186.31 M(+510.4%) |
| Sept 2011 | - | $30.52 M(+50.1%) |
| June 2011 | - | $20.33 M(+1.0%) |
| Mar 2011 | - | $20.12 M(-57.4%) |
| Dec 2010 | $47.21 M(-53.1%) | $47.21 M(-77.7%) |
| Sept 2010 | - | $211.99 M(-14.4%) |
| June 2010 | - | $247.70 M(-4.8%) |
| Mar 2010 | - | $260.13 M(+158.7%) |
| Dec 2009 | $100.55 M(+17.1%) | $100.55 M(+60.3%) |
| Sept 2009 | - | $62.74 M(+27.6%) |
| June 2009 | - | $49.17 M(+190.0%) |
| Mar 2009 | - | $16.95 M(-80.3%) |
| Dec 2008 | $85.87 M(+274.4%) | $85.87 M(-14.3%) |
| Sept 2008 | - | $100.21 M(-8.6%) |
| June 2008 | - | $109.65 M(+84.4%) |
| Mar 2008 | - | $59.46 M(+159.2%) |
| Dec 2007 | $22.94 M(-24.1%) | $22.94 M(-54.8%) |
| Sept 2007 | - | $50.72 M(+124.6%) |
| June 2007 | - | $22.59 M(+15.2%) |
| Mar 2007 | - | $19.61 M(-35.1%) |
| Dec 2006 | $30.23 M(+37.6%) | $30.23 M(+149.4%) |
| Sept 2006 | - | $12.12 M(-16.7%) |
| June 2006 | - | $14.54 M(-33.5%) |
| Mar 2006 | - | $21.86 M(-0.5%) |
| Dec 2005 | $21.97 M(+50.4%) | $21.97 M(-5.0%) |
| Sept 2005 | - | $23.12 M(+85.1%) |
| June 2005 | - | $12.49 M(-2.5%) |
| Mar 2005 | - | $12.81 M(-12.3%) |
| Dec 2004 | $14.61 M(-82.2%) | $14.61 M(-78.2%) |
| Sept 2004 | - | $67.11 M(+0.0%) |
| June 2004 | - | $67.09 M(+31.1%) |
| Mar 2004 | - | $51.19 M(-37.5%) |
| Dec 2003 | $81.92 M(+108.1%) | $81.92 M(+27.5%) |
| Sept 2003 | - | $64.27 M(+89.6%) |
| June 2003 | - | $33.90 M(-13.5%) |
| Mar 2003 | - | $39.18 M(-0.5%) |
| Dec 2002 | $39.36 M(+140.7%) | $39.36 M(-50.6%) |
| Sept 2002 | - | $79.72 M(+257.6%) |
| June 2002 | - | $22.30 M(-53.1%) |
| Mar 2002 | - | $47.54 M(+190.7%) |
| Dec 2001 | $16.36 M(-56.7%) | $16.36 M(-29.1%) |
| Sept 2001 | - | $23.07 M(-47.1%) |
| June 2001 | - | $43.59 M(-45.0%) |
| Mar 2001 | - | $79.22 M(+109.5%) |
| Dec 2000 | $37.81 M(+1766.3%) | $37.81 M(+57.9%) |
| Sept 2000 | - | $23.94 M(-51.8%) |
| June 2000 | - | $49.63 M(+2814.1%) |
| Mar 2000 | - | $1.70 M |
| Dec 1999 | $2.03 M | - |
FAQ
- What is Lexicon Pharmaceuticals annual cash & cash equivalents?
- What is the all time high annual cash & cash equivalents for Lexicon Pharmaceuticals?
- What is Lexicon Pharmaceuticals annual cash & cash equivalents year-on-year change?
- What is Lexicon Pharmaceuticals quarterly cash and cash equivalents?
- What is the all time high quarterly cash and cash equivalents for Lexicon Pharmaceuticals?
- What is Lexicon Pharmaceuticals quarterly cash and cash equivalents year-on-year change?
What is Lexicon Pharmaceuticals annual cash & cash equivalents?
The current annual cash & cash equivalents of LXRX is $22.46 M
What is the all time high annual cash & cash equivalents for Lexicon Pharmaceuticals?
Lexicon Pharmaceuticals all-time high annual cash & cash equivalents is $202.99 M
What is Lexicon Pharmaceuticals annual cash & cash equivalents year-on-year change?
Over the past year, LXRX annual cash & cash equivalents has changed by -$23.88 M (-51.53%)
What is Lexicon Pharmaceuticals quarterly cash and cash equivalents?
The current quarterly cash and cash equivalents of LXRX is $34.55 M
What is the all time high quarterly cash and cash equivalents for Lexicon Pharmaceuticals?
Lexicon Pharmaceuticals all-time high quarterly cash and cash equivalents is $260.13 M
What is Lexicon Pharmaceuticals quarterly cash and cash equivalents year-on-year change?
Over the past year, LXRX quarterly cash and cash equivalents has changed by +$13.44 M (+63.62%)